AstraZeneca 'disappointed but confident' over Nexium patent decision in Europe
This article was originally published in Scrip
Executive Summary
AstraZeneca has informed Scrip that it "has confidence in its intellectual property portfolio protecting Nexium (esomeprazole)" following the decision of the European Patent Office to revoke one of its patents covering the proton pump inhibitor for oral administration (patent EP 1 020 461) following thirteen oppositions from generic drug manufacturers including Teva. However, it was "disappointed" by the ruling.